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Impact of 5 mg/kg caffeine, chance of receiving caffeine (stimulus expectancies), and expectations of effects of 
caffeine (response expectancies) on objective (heart rate (HR), systolic/diastolic blood pressure (SBP/DBP), 
measures of heart rate variability (HRV), and reaction time (RT)) and subjective variables were investigated in a 
double-blind, placebo-controlled experiment with a no-treatment group. Participants were 107 undergraduate 
university students (mean age 22.3 ± 3.96 years). Consumption of 5 mg/kg caffeine had an impact on participants’ 
SBP, standard deviation of normal heartbeat intervals, HR (decrease), and subjective experience 40 minutes later 
even after controlling for respective baseline values, stimulus and response expectancies, and habitual caffeine 
consumption. No effects on DBP, high frequency component of HRV, the ratio of low- and high-frequency, and RT 
were found. Beyond actual caffeine intake, response expectancy score was also a determinant of subjective 
experience which refers to a placebo component in the total effect. Actual autonomic (SBP, HR) changes and 
somatosensory amplification tendency, however, had no significant impact on subjective experience. Placebo 
reaction plays a role in the subjective changes caused by caffeine consumption but it has no impact on objective 
variables. Conditional vs deceptive administration of caffeine (i.e. stimulus expectancies) had no impact on any 
assessed variable.
Keywords: double-blind versus deceptive administration, caffeine, placebo, blood pressure, heart rate, heart rate 
variability, expectations
Caffeine is one of the most widely consumed behaviorally active substances in the world, its 
physiological and psychological effects (e.g. increasing alertness, enhancing vigilance, 
reducing fatigue, elevating blood pressure) are widely known and utilized (1, 28, 38, 39). 
Although caffeine acts in several different ways, its most important biological effect is 
inhibition of adenosin receptors in the brain (1, 32). Pharmacological effects of caffeine are 
usually well observable in animal models (39). In the case of humans, however, the 
phenomenon is more complicated: anticipation of caffeine intake and expectations about the 
effects of caffeine may also play a role in the final response pattern (7, 8, 13, 25). Expectations 
or expectancies are categorized into three groups (45): (1) stimulus expectancies refer to 
one’s belief that he is about to ingest an active substance (in the case of caffeine, these 
expectancies are triggered, e.g. by taste and smell of coffee); (2) response expectancies are 
expectations about the responses evoked by the drug taken (e.g. the knowledge that caffeine 
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elevates blood pressure and improves awareness); and (3) expectancies about the consequences 
of the consumption of the given drug (e.g. social consequences of regularly having a coffee 
with colleagues). According to studies on alcohol, caffeine, and other substances, expectancies 
often moderate pharmacological effects of psychoactive drugs and can even mimic certain 
pharmacological effects in the absence of any active substance (i.e. when participants receive 
placebo (45)).
In addition to sensory stimuli, verbal information has also an impact on stimulus 
expectancies. In the case of double-blind RCT, participants are informed that they will receive 
an active substance or placebo, and they are also aware of the likelihood of receiving the 
active substance (e.g. 0.5 or 0.7) – this is called conditional (or double-blind) administration 
(17, 18). From methodological point of view, this way of administration as opposed to 
deceptive administration when patients firmly believe that they receive the active substance 
(likelihood = 1.0) may lead to underestimation of the magnitude of the placebo effect. 
Deceptive administration may have a higher external validity, however, it cannot be used in 
RCTs for ethical reasons.
Caffeine may serve as an appropriate model to investigate this problem as it is legal, 
widely used, and there exists a placebo (i.e. decaffeinated coffee) that is not easily 
distinguishable from the active preparation. In an early study (18), individuals receiving 
caffeine placebo with deceptive information showed higher HR and subjective tension than 
the conditional information group (no differences in blood pressure were reported). In a 
second study (17) using a more sophisticated design including groups that received caffeine 
or placebo with deceptive, conditional, or negative (i.e. participants were told that the drink 
contained no caffeine) information and measurements 15, 30, and 45 minutes following the 
administration, effects of information and information-caffeine interactions were found. For 
example, deceptive information had an impact on participants’ alertness 15 minutes after 
ingestion in both the caffeine and placebo groups, whereas pharmacological effect of caffeine 
was measurable in the next period. Difference between the effects of deceptive and double-
blind information was found in the case of DB, while SBP was only influenced by the actual 
caffeine intake. In summary, the information given to participants about the likelihood of 
receiving the active substance (stimulus expectancy) had an impact on certain variables in 
both the placebo and the caffeine groups. Interestingly, in other studies with placebo-groups 
only (46, 47) or with placebo and caffeine groups (24), no such differences were found.
In studies that operated with deceptive administration only, mixed and often contradictory 
results were reported in various cognitive tasks. A synergistic caffeine-information effect was 
reported in vigilance and psychomotor tasks (8–10), while no or minimal interaction was 
found in other experiments (7). The manipulation of response expectancies (beliefs about the 
effects of caffeine) also changed participants’ reactions (29), although sometimes in the 
opposite direction (i.e. stimulant instruction had a negative impact on reaction time) (14). 
Abbreviations
BP = blood pressure
DBP = diastolic blood pressure
SBP = systolic blood pressure
HR = heart rate
HRV = heart rate variability
HF = high frequency components of HRV (0.15–0.4 Hz)
LF = low frequency components of HRV (0.04–0.15 Hz)
LF/HF = the ratio of low- and high-frequency power
RCTs = randomized controlled trials
SDNN =  standard deviation of normal to normal R-R 
intervals
SRQ = self-reported questionnare
SSAS = Somatosensory Amplification Scale
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Autonomic variables (HR, SBP, DBP) as opposed to subjective variables have usually not 
been influenced by verbal information about the caffeine content of the drink (12, 21, 36, 42).
In addition to information given to participants, lack of appropriate control group 
represents a further methodological problem in many studies investigating the placebo effect. 
Changes in placebo groups are attributable to many factors beyond the genuine placebo-
reaction (e.g. natural fluctuations of the given state or symptom, regression to the mean, etc.), 
thus a non-treated control group (natural history group) is needed to exclude these disturbing 
factors (4). In many studies investigating the effects of placebo caffeine, no natural history 
group was included (usually the so-called balanced placebo design was used), and no research 
has been published to date that studied these effects on groups receiving placebo caffeine or 
real caffeine with deceptive or conditional information and with a non-treated control group.
The present study aimed to fill this gap and to study the placebo caffeine phenomenon 
in a complex way. It was hypothesized that actual intake of caffeine and/or higher stimulus 
expectancies would increase participants’ BP, HR, HRV-HF, HRV-LF/HF and reaction time, 
and would lead to more self-reported caffeine-related symptoms. Moreover, we have 
hypothesized that peripheral autonomic variables, actual caffeine intake, stimulus and 
response expectancies, and proneness to amplify subjective symptoms (somatosensory 
amplification) would have an impact on perceived effects of caffeine.
Materials and Methods
Participants
107 undergraduate university students (mean age 22.3 ± 3.96 years; 39.3% male) volunteered 
to participate in the experiment. Students received no reward for their participation. 
Individuals with known cardiovascular problems or caffeine sensitivity were excluded from 
the study.
Objective measurements
Cardiovascular data (HR, HRV, BP) were recorded. Electrodes were placed to the distal ends 
of the collarbones and to the anterior superior iliac spines. HR and HRV (SDNN, HF, LF/HF) 
values were calculated from one-minute intervals of resting sessions, SBP and DBP were 
measured at the end of the resting sessions. Reaction time measurement was carried out using 
the PsychLabWin v1.1 software. The measurement consisted of 90 trials, it took approximately 
5–7 minutes to complete.
Questionnaires
Habitual caffeine consumption were assessed using a single question (“How often do you 
drink a coffee?”) to be rated on a 5-pont Likert-scale (never/sometimes/several times a week/
once a day/several times a day).
Expectancies about the effects of coffee (response expectancies) and actually experienced 
effects were measured using the SRQ-scale developed by Rush (15, 34). The SRQ assesses 
the existence of sixteen psychic (e.g. alertness, concentration) and somatic (e.g. palpitation, 
headache) caffeine-related symptoms on a 4-point Likert-scale (not at all/a bit/to great 
extent/extremely). In the case of T1 (baseline) and T2 measurements, participants were asked 
to rate the actual severity of the symptoms and conditions, while they had to mark expected 
severity of symptoms in the expectancy measurement. Internal consistency (Cronbach’s 
alpha coefficients) of the scale was between 0.72 and 0.80.
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Proneness to amplify perceived symptoms was assessed by the 10-item SSAS (3). 
Somatosensory amplification refers to the tendency to experience somatic sensations as 
intense, noxious, and disturbing. The Hungarian version proved to be psychometrically 
sound in previous studies (20), its Cronbach’s α coefficient was rather low (0.63) in the 
present study.
Procedure
The whole procedure was approved by the Ethical Committee of the Faculty of Education 
and Psychology, Eötvös Loránd University, Hungary. The procedure met the requirements of 
the World Medical Association Declaration of Helsinki and the Decree No 23/2002 (V. 09.) 
EüM on Medical Trials Made on Human Subjects. Participants were asked to avoid caffeine 
intake 12 hours before the experiment. Upon arrival, participants received detailed information 
about the experimental procedure and signed the informed consent form. Following the 
placement of ECG-electrodes and the completion of T1 (baseline) measurements (personal 
data, actual and expected SRQ, SSAS, cardiovascular data, and reaction time), they were 
arranged in five groups in a quasi-random manner to maintain gender ratio. One group 
(natural history group, N = 22) had to drink a cup of room-temperature (approx. 22–23 ºC) 
water with the instruction that it contains no caffeine (stimulus expectancy in this group was 
0.0). The remaining four groups drunk a cup of decaffeinated warm (approx. 40–45 ºC) 
coffee containing 5 mg/kg caffeine or no caffeine. Two groups (conditional caffeine group, N 
= 20 and conditional placebo group, N = 18) were told that they would drink caffeinated or 
decaffeinated coffee with equal chance (stimulus expectancy = 0.5) and they received 
caffeinated or caffeine-free coffee, respectively. The last two groups (caffeine group, N = 25 
and deceived placebo group, N = 22) were informed that they would receive a cup of strong 
coffee (stimulus expectancy = 1.0) but they received caffeinated or decaffeinated coffee, 
respectively. Drinks were serviced by an assistant in a separate room thus the experimenter 
was not aware of the participants’ group affiliation in the remaining part of the experiment. 
Following the ingestion of the drink, participants were asked to relax for 35 minutes, then 
they had to rate the perceived strength of the coffee they consumed on a 5-point Likert-scale. 
Post-experimental analysis revealed that nobody in the deceived caffeine group or in the 
caffeine group thought that he or she received decaffeinated coffee, thus the deception was 
considered successful. Finally, T2 data (actual SRQ, cardiovascular data, and reaction time) 
were recorded, and participants were informed about their group affiliation.
Statistical analysis
Descriptive statistics of the assessed variables were presented in Table I. As we intended to 
investigate the contribution of multiple factors (e.g. respective baseline value, habitual 
caffeine consumption, various forms of expectancies, etc.) to the results at T2 and data were 
appropriate for parametric analysis, multiple linear regression analysis was used. Eight 
multiple linear regression analyses were carried out with SBP, DBP, HR, HRV (SDNN, HF, 
LF/HF), reaction time, and SRQ values at T2 as dependent variables, respectively. In each 
analysis, stimulus expectancies (told likelihood of caffeine intake), actual caffeine intake (0 
= no, 1 = yes), habitual caffeine consumption, response expectancies (expected SRQ score), 
and the respective baseline (T1) value were used as independent (predictor) variables. 
Variables were entered in one step using the ENTER method.
To explore factors influencing subjective experience, a further analysis with T2 SRQ 
score as dependent variable was carried out. In the first step of this analysis, changes in 
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autonomic variables between T1 and T2 (ΔSBP, ΔHR), actual caffeine intake, and baseline 
SRQ score were entered. In the second step, stimulus and response expectancies, and 
somatosensory amplification score were stepped in the equation.
Table I. Descriptive statistics (means and SDs) of the assessed variables in the five groups
Group 1
(control)
Group 2
(conditional 
placebo)
Group 3
(conditional 
caffeine)
Group 4
(deceived 
placebo)
Group 5
(caffeine)
N 22 18 20 22 25
Habitual caffeine 
consumption
2.59 ± 1.33 2.83 ± 1.65 2.15 ± 1.03 3.36 ± 1.46 3.76 ± 1.12
Response expectancies 27.13 ± 6.69 26.94 ± 5.36 26.70 ± 5.23 28.18 ± 5.43 31.04 ± 5.20
SSAS 30.72 ± 6.52 28.38 ± 7.57 32.05 ± 4.19 29.72 ± 5.98 31.36 ± 5.34
SBP at T1 122.40 ± 13.44 113.77 ± 10.46 115.90 ± 11.92 124.59 ± 11.32 121.92 ± 13.79
SBP at T2 116.86 ± 12.13 114.72 ± 9.91 121.90 ± 11.96 123.05 ± 10.29 122.08 ± 16.81
DBP at T1 73.22 ± 10.88 70.61 ± 7.66 69.10 ± 6.36 74.04 ± 9.90 69.92 ± 9.09
DBP at T2 73.09 ± 8.28 70.05 ± 7.01 72.10 ± 6.75 73.85 ± 9.94 72.08 ± 12.85
HR at T1 77.05 ± 14.11 73.83 ± 11.96 73.90 ± 10.09 76.72 ± 11.60 79.16 ± 13.77
HR at T2 72.75 ± 12.51 69.22 ± 7.49 66.50 ± 8.04 74.54 ± 15.47 69.20 ± 12.13
HRV-SDNN at T1 213.05 ± 25.46 213.77 ± 17.88 213.20 ± 14.70 212.59 ± 19.00 208.75 ± 20.07
HRV-SDNN at T2 219.50 ± 26.60 220.27 ± 12.65 225.55 ± 14.84 216.68 ± 17.60 221.64 ± 19.77
HRV-HF at T1 24.15 ± 7.37 20.27 ± 7.33 22.55 ± 6.96 21.81 ± 8.39 22.25 ± 7.18
HRV-HF at T2 25.45 ± 8.98 20.22 ± 6.55 21.55 ± 5.72 23.86 ± 11.84 19.64 ± 5.23
HRV-LF/HF at T1 0.54 ± 0.36 0.50 ± 0.44 0.48 ± 0.48 0.45 ± 0.37 0.50 ± 0.27
HRV-LF/HF at T2 0.46 ± 0.27 0.38 ± 0.36 0.29 ± 0.14 0.47 ± 0.29 0.50 ± 0.29
RT at T1 352.70 ± 43.57 359.10 ± 40.24 350.94 ± 29.94 381.93 ± 59.87 361.41 ± 57.40
RT at T2 335.25 ± 42.17 326.05 ± 24.35 332.49 ± 29.92 358.03 ± 51.58 336.38 ± 54.24
SRQ at T1 13.63 ± 4.91 14.16 ± 4.85 14.90 ± 4.33 15.90 ± 5.45 11.84 ± 3.54
SRQ at T2 13.40 ± 4.39 14.33 ± 5.73 15.55 ± 5.44 15.68 ± 4.62 16.40 ± 5.50
Results
Descriptive statistics of the assessed variables were presented in Table I, and results of the 
eight multiple regression analyses were presented in Table II. In summary, the equation was 
not significant in the case of LF/HF. Beyond respective baseline (T1) values, actual caffeine 
intake was a significant predictor of T2 values of SBP, HR (decrease), SDNN, and SRQ. 
Actual caffeine intake had no impact on values of DBP, HF, and RT at T2. Habitual caffeine 
consumption and stimulus expectancies (told likelihood of caffeine intake) did not influence 
any variables at T2. Response expectancy score (expected effects of caffeine) was a significant 
predictor of SRQ score at T2. It had no impact, however, on any objective variables.
As for the regression analysis exploring factors behind subjective experience, the impact 
of baseline SRQ score (β = 0.461; p < 0.001) and actual caffeine intake (β = 0.272; p < 0.01) 
was significant (R2 = 0.253) in the first equation. In the final equation, both of these variables 
remained significant (β = 0.477; p < 0.001, and β = 0.202; p < 0.05, respectively) and response 
expectancy score also reached the significance level (β = 0.264; p < 0.01) (R2 = 0.334).
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Table II. Results of multiple linear regression analyses
Variable at T2 Significant predictors Not significant predictors
SBP (R2 = 0.471) SBP at T1 (β = 0.663; p < 0.001)
actual caffeine intake (β = 0.134; p < 0.1)
habitual caffeine consumption
told likelihood of caffeine intake
expected subjective effects
DBP (R2 = 0.349) DBP at T1 (β = 0.602; p < 0.001) actual caffeine intake
habitual caffeine consumption
told likelihood of caffeine intake
expected subjective effects
HR (R2 = 0.672) HR at T1 (β = 0.798; p < 0.001)
actual caffeine intake (β = –0.210; p < 0.001)
habitual caffeine consumption
told likelihood of caffeine intake
expected subjective effects
SDNN (R2 = 0.707) SDNN at T1 (β = 0.831; p < 0.001)
actual caffeine intake (β = 0.175; p < 0.01)
habitual caffeine consumption
told likelihood of caffeine intake
expected subjective effects
HF (R2 = 0.119) HF at T1 (β = 0.348; p < 0.001) actual caffeine intake
habitual caffeine consumption
told likelihood of caffeine intake
expected subjective effects
LF/HF – LF/HF at T1
actual caffeine intake
habitual caffeine consumption
told likelihood of caffeine intake
expected subjective effects
RT (R2 = 0.673) RT at T1 (β = 0.830; p < 0.001) actual caffeine intake
habitual caffeine consumption
told likelihood of caffeine intake
expected subjective effects
SRQ (R2 = 0.338) SRQ at T1 (β = 0.489; p < 0.001)
expected subjective effects (β = 0.271; p < 0.01)
actual caffeine intake (β = 0.155; p < 0.1)
habitual caffeine consumption
told likelihood of caffeine intake
Discussion
In a double-blind, placebo-controlled experiment with a natural history group, consumption 
of 5 mg/kg caffeine had an impact on participants’ SBP, HRV-SDNN, HR (decrease), and 
subjective experience 40 minutes later even after controlling for respective baseline values, 
stimulus and response expectancies, and habitual caffeine consumption. No effects on DBP, 
HRV-HF, HRV-LF/HF, and reaction time were found. Stimulus expectancies (i.e. known 
chance of receiving caffeine) had no impact on any assessed variable. Beyond actual caffeine 
intake, response expectancy score was also a determinant of subjective experience which 
refers to a placebo component in the total effect. Actual autonomic (SBP, HR) changes and 
somatosensory amplification tendency, however, had no significant impact on subjective 
experience.
Intake of 5 mg/kg caffeine elevated participants’ SBP, decreased their HR, and had not 
influenced DBP in the current study. As caffeine had an impact on HRV-SDNN which reflects 
all cyclic components responsible for HR variability and had no impact on the more specific 
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HF and LF/HF indices, no conclusions can be drawn regarding the autonomic background of 
this change. Although the hypertensive effect of caffeine is generally accepted (6, 11, 12, 17, 
22, 24, 35), it was not demonstrated in all studies (17, 37). HR-related results are also mixed. 
While no changes following caffeine consumption were detected in some studies (6, 11, 12, 
17, 24, 37), a significant decrease in HR was reported in others (22, 35, 40, 49). Reduction of 
HR possibly reflects a baroreceptor mediated response to pressor action (28). Caffeine-
related changes in various indices of HRV were investigated in several placebo-controlled 
studies with often contradictory results (no data from the caffeine-placebo literature is 
available, though). Increases in the HF component reflecting parasympathetic (vagal) activity 
were demonstrated in the majority of the studies (16, 27, 33, 50). No changes in SDNN, HF, 
and LF/HF were found in two studies (31, 48) and significant decreases were reported in a 
third paper (41). As for the LF/HF ratio, usually a significant increase has been reported 
which is attributed to the sympathetic activating effect of caffeine (5, 19, 26). These 
contradictory results are usually explained by differences in experimental settings and 
participants’ previous experiences with caffeine (2, 23).
Participants’ reaction time was not influenced either by caffeine intake or by stimulus 
expectancies. This finding is in accordance with the results of previous studies (24, 35). In the 
study of Nash et al. (24), negative results were obtained following the intake of both 125 mg 
and 325 mg caffeine, and the latter dosage is comparable to that used in the recent study. 
According to these findings, caffeine may affect vigilance and psychomotor performance but 
has no direct impact on reaction time.
The only variable in the experiment that was influenced by response expectancies was 
the SRQ-score, i.e. caffeine related symptoms as experienced by the participants. Although 
actual caffeine consumption also impacted participants’ subjective experience, according to 
the results of the last regression analysis, this effect could not be tracked down to peripheral 
autonomic changes (HR and SBP). Consequently, the moderating factor between subjective 
experience and caffeine intake may have been caffeine’s central stimulating effect. 
Somatosensory amplification tendency did not prove to be a predictor of subjective state 
either, possibly because it refers to a tendency of amplifying aversive internal states and the 
SRQ consists of mainly positive items.
Changes in subjective variables are the most often mentioned effects of placebos, in 
both caffeine-related and medical research. A hypothesis proposed by Benedetti is that the 
most important mechanism behind objective (autonomic) changes caused by placebos is 
classical conditioning, while conscious expectations affect mainly subjective variables (4). 
Although this proposal cannot be regarded as a strict rule, it is in accordance with the majority 
of placebo-related findings and this is the case in the present study, too.
As for the role of conditional vs. deceptive administration, no significant impact on any 
outcome measure was found in the current experiment. This negative finding is in accordance 
with the results of other caffeine studies (24, 46, 47), while differences between the effects of 
the two administration methods were found in pain-related clinical and experimental placebo 
studies (30, 43, 44). According to these findings, results obtained from laboratory experiments 
using caffeine cannot be generalized to medical problems (i.e. external validity of caffeine 
studies seems to be quite low). Caffeine is mainly used by healthy individuals for recreational 
purposes and to improve cognitive abilities, and this context is clearly different from illness-
related conditions.
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